The antibody specialist reported broadly flat results for the year to 30 June 2026. Lower vitamin D sales and currency headwinds were offset by growth in its neurology portfolio, and the company kept its total dividend at 150p per share.

What was announced

Bioventix plc (LSE:BVXP), which makes sheep monoclonal antibodies used in diagnostic blood tests, published results for the year ended 30 June 2026 on 26 October 2026. Revenue fell 0.8% to £13.0m, from £13.1m. The exact turnover figures were £12,971,744 and £13,115,869. At the average exchange rates of 2024/25, revenue would have been £13.3m.

Profit before tax rose 1% to £10.2m (£10,227,424), from £10.1m (£10,095,915). On a constant-currency basis it would have been £10.5m. Profit after tax was £7,614,653, against £7,584,442 a year earlier. Basic earnings per share were 145.74p (2025: 145.27p), and diluted earnings per share were 143.62p (2025: 143.35p).

Dividends and cash

The board declared a second interim dividend of 80p per share, the same as last year. Together with the first interim dividend of 70p, that gives a total of 150p for the year, matching 2025. The second interim dividend goes ex-dividend on 5 November 2026, with a record date of 6 November and payment on 20 November 2026.

The company said it generated about £8m of cash during the year and returned almost all of it to shareholders as dividends. Cash at the year end was £5.3m (£5,264,706), compared with £5.1m a year earlier. There are two internal inconsistencies in the published document. One section shows the second interim dividend as "xx pence", and one note gives the 2025 dividend as 157 pence. The highlights state 80p and 150p.

Products and currency

Vitamin D remains the largest product. Sales of the vitD3.5H10 antibody fell 4% to £6.35m, which the company attributed to a difficult downstream market, particularly in China. Troponin sales were about £1.4m, in line with 2024/25. Bioventix (LSE:BVXP) said its Siemens troponin revenue will end in June 2032 for contractual reasons. A progesterone antibody contract was terminated during the year, removing annual sales of about £400k from future revenue.

The neurology portfolio grew. Tau and neurology royalties tripled to £257k, from £75k. The company said this reflected greater use of its antibodies in non-clinical laboratory assays run by newer companies with high-sensitivity testing platforms. Five Tau antibodies are now produced at scale, and two eMTBR antibodies are due to move into production in the fourth quarter of calendar 2026.

Currency was a headwind. Bioventix estimates that 50% to 60% of its sales are linked to the US dollar. It said exchange-rate movements reduced turnover by about £300k on a constant-currency comparison. Favourable movements between invoicing and settlement produced a gain of about £62k.

The company also outlined smaller development projects. It hopes to have a paracetamol lateral flow assay before the year end, and it plans field trials of a pyrene lateral flow test with firefighters in 2027. Bioventix employs 12 full-time equivalents, with 14 staff in total.

Outlook and what to watch

Bioventix said it expects the year to 30 June 2027 to follow a similar pattern to the year just reported. Core revenue will face headwinds and will be increasingly supplemented by Tau and neurology sales. Over the longer term, it expects the neurology portfolio to offset pressure on legacy antibodies, although it said the timing of that growth is difficult to forecast.

The statement was signed by chief executive Peter Harrison and non-executive chairman I J Nicholson.

Key points to watch include the pace of Tau royalty growth, the start of eMTBR production, and any stabilisation in vitamin D demand in China. The planned end of Siemens troponin revenue in 2032 and the loss of the progesterone contract are known future gaps. The neurology portfolio will need to fill them.